Clinical characteristics of the survivin group and diffuse large B-cell lymphomas patients enrolled in the LNH87 protocol
| Characteristic . | Survivin group (n = 222) . | Diffuse large B-cell lymphoma (n = 1182) . | P . |
|---|---|---|---|
| Median age, y | 56 | 57 | |
| Clinical stage III, IV, % | 55 | 57 | .51 |
| Bulky disease > 10 cm, % | 44 | 51 | .07 |
| Bone marrow involvement, % | 15 | 17 | .59 |
| Entranodal sites > 1, % | 29 | 30 | .78 |
| ECOG PS > 1, % | 23 | 26 | .50 |
| Lactate dehydrogenase > 1N, % | 60 | 57 | .39 |
| IPI score, % | .87 | ||
| Low (0-1) | 41 | 39 | |
| Low intermediate (2) | 21 | 23 | |
| High intermediate (3) | 21 | 20 | |
| High (4-5) | 17 | 18 | |
| Evolution, % | .77 | ||
| Complete remission | 64 | 65 |
| Characteristic . | Survivin group (n = 222) . | Diffuse large B-cell lymphoma (n = 1182) . | P . |
|---|---|---|---|
| Median age, y | 56 | 57 | |
| Clinical stage III, IV, % | 55 | 57 | .51 |
| Bulky disease > 10 cm, % | 44 | 51 | .07 |
| Bone marrow involvement, % | 15 | 17 | .59 |
| Entranodal sites > 1, % | 29 | 30 | .78 |
| ECOG PS > 1, % | 23 | 26 | .50 |
| Lactate dehydrogenase > 1N, % | 60 | 57 | .39 |
| IPI score, % | .87 | ||
| Low (0-1) | 41 | 39 | |
| Low intermediate (2) | 21 | 23 | |
| High intermediate (3) | 21 | 20 | |
| High (4-5) | 17 | 18 | |
| Evolution, % | .77 | ||
| Complete remission | 64 | 65 |
ECOG PS indicates performance status according to the Eastern Cooperative Oncology Group scale.